AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases Seven presentations by AC Immune and its partners at AAT-AD/PD TM New data on early-stage TDP-43 and alpha

AC Immune Presents the Latest Preclinical

Data on Novel Drug Targets for Neurodegenerative Diseases

Seven presentations by AC Immune and its

partners at AAT-AD/PDTM

data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates

anti-alpha-synuclein therapeutic antibody candidate has advanced into preclinical development to treat Parkinson's disease

and other synucleinopathies

Lausanne, Switzerland, April, 2 2020

- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company today outlined new preclinical data

that will be presented at this year's first ever online AAT-AD/PDTM Focus Meeting from April 2-5, 2020.

The presentations describe proof-of-concept preclinical data for lead candidates in AC Immune's therapeutic and diagnostic

programs targeting TDP-43 and alpha-synuclein. These pathological proteins represent targets of increasing interest for the treatment

of neurodegenerative diseases, and AC Immune's programs are amongst the most advanced in the field.

Prof. Andrea Pfeifer, CEO of AC Immune

SA, commented: "Our heritage as a leader in delivering cutting-edge science and our strong cash position provides the

foundation to continue advancing data on novel targets for neurodegenerative diseases. The aggregation of pathological forms of

TDP-43 and alpha-synuclein proteins are hallmarks of numerous neurodegenerative diseases, including neuroOrphan indications such

as frontotemporal lobar degeneration, amyotrophic lateral sclerosis and multiple system atrophy. As novel therapeutic targets in

Alzheimer's disease (AD), it has been shown that patients with a high degree of Abeta and Tau pathologies also show a high

level of alpha-synuclein and/or TDP-43 co-pathology."

Prof. Pfeifer continued: "The

prevalence of co-pathologies in AD and other neurodegenerative diseases highlights the need for the precision medicine pioneered

by AC Immune and the opportunity for earlier and more accurate diagnosis. As one of the most advanced programs targeting TDP-43,

with in vivo proof-of-concept data, we intend to develop our antibody candidate in a neuroOrphan indication. Leading the

way in developing the first TDP-43 positron emission tomography (PET) imaging agent, we hope to improve the timing and accuracy

of diagnoses in neurodegenerative disease, representing our complementary diagnostics portfolio."

TDP-43 and alpha-synuclein pathologies have

been shown to start from a focal point in the brain and progressively spread to other brain regions with disease progression. Antibody-mediated

clearance of pathological TDP-43 and alpha-synuclein represent attractive strategies for therapeutic intervention. Availability

of non-invasive tools like PET imaging agents would allow accurate diagnosis and monitoring of disease progression, and would potentially

enable longitudinal drug efficacy measurements in patients.

The three preclinical studies that will

be presented at AAT-AD/PD illustrate how AC Immune continues to leverage its proprietary technology platforms, SupraAntigenTM

and MorphomerTM to develop product candidates against pathologies associated with TDP-43 and alpha-synuclein.

Anti-TDP-43 antibody

Data to be presented for the first time,

shows that the Company's lead TDP-43 antibody candidate mitigated TDP-43 neuropathology in a mouse model of TDP-43 proteinopathies.

The unique pool of TDP-43 antibodies generated by AC Immune's proprietary SupraAntigenTM platform also allowed

development of highly sensitive assays for detection and quantification of total and disease-specific TDP-43 isoforms in biofluids

with the potential for clinical biomarker evaluation.

MorphomerTM TDP-43 imaging

for a first in class TDP-43 PET tracer will illustrate how the lead candidate was identified and optimized. The lead

candidate, generated using the proprietary MorphomerTM platform, demonstrates binding to brain-derived pathological

TDP-43 aggregates with high affinity and, importantly, direct target engagement on patient brain tissue.

Anti-alpha-synuclein antibody

Using the SupraAntigenTM platform,

antibodies with high-affinity for aggregated alpha-synuclein have been developed which prevent the intercellular spreading of toxic

alpha-synuclein species. Data, presented for the first time, demonstrate that lead candidate antibodies reduce the de novo

formation of alpha-synuclein aggregates in vitro and significantly decrease spreading of alpha-synuclein pathology in a

mouse model of human disease. A lead therapeutic candidate has been advanced into preclinical development to treat Parkinson's

disease and other synucleinopathies.

Prof. Pfeifer added: "AC Immune

continues to deliver on its Roadmap to Successful Therapies for Neurodegenerative Diseases,

enabling precision medicine by selecting clinical study populations based on the presence of the underlying proteinopathies."

AAT-AD/PD features seven presentations

by AC Immune and its partners:

Date: April 2, 2020 | 11:40 - 12:00

Presenter: Oral presentation

Christina Rabe (Roche program)

Date: April 2, 2020 | 12:40 - 1:00

Presenter: Oral presentation

by Carla Palleis (Life Molecular Imaging program)

Date: April 2, 2020 | 6:15 - 6:35

Presenter: Oral presentation by Marija Vukicevic

Date: April 3, 2020 | 9:29 - 9:35

Presenter: Short oral poster presentation by Tariq Afroz

Date: April 3, 2020 | 3:10 - 3:30

Presenter: Oral presentation Tariq Afroz

Date: April 3, 2020 | 5:50 - 6:10

Presenter: Oral presentation Andrew Stephens (Life Molecular Imaging program)

Date: April 5, 2020 | 8:55 - 9:15

Presenter: Oral presentation Elpida Tsika

presentations are available to download from the AAT-AD/PDTM website for those registered to attend the congress.

Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision

medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM,

to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose,

prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic

and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical

companies including Roche/Genentech, Lilly and Janssen.

For further information, please contact:

Forward looking statements

This press release contains statements that

constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section

21E of the Securities Exchange

Act of 1934. Forward-looking statements are statements other than historical fact and may include

statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In

some cases, you can identify these statements by forward-looking words such as "may," "might," "will,"

"should," "expects," "plans," "anticipates," "believes," "estimates,"

"predicts," "projects," "potential," "outlook" or "continue," and other

comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve

significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from

those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3.

Key Information - Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's

Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only

as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future

developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their

entirety by this cautionary statement.